Key result
This review summarizes recent developments in the field of biomarkers of response to anti-VEGF drugs, addressing the lack of accurate ways to assess response beyond conventional imaging.
Why the study?
What are the recent developments in biomarkers of response to anti-VEGF drugs?
What are the recent developments in biomarkers of response to anti-VEGF drugs?
This review highlights the need for and recent developments in accurate biomarkers to assess response to anti-angiogenic therapies beyond conventional imaging.
Promising biomarkers for anti-VEGF response are emerging; leaves open their clinical utility pending prospective validation.
Anti-angiogenic agents targeting tumour vasculature have an established place in clinical practice, and new data are constantly emerging. However, despite rapid clinical uptake, a very large number of questions regarding these agents remain unanswered. One of the main hurdles in clinical practice is lack of accurate and feasible ways of assessing response to drug beyond tumour reduction on conventional imaging. This review summarises recent developments in the field of biomarkers of response to anti-VEGF drugs.
No takes yet. Share an insight, caveat, or question.
Michael et al. (2010) conducted a review in Tumour. Anti-VEGF drugs was evaluated. This review summarizes recent developments in the field of biomarkers of response to anti-VEGF drugs, addressing the lack of accurate ways to assess response beyond conventional imaging.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: